{
  "@context": "aku-v2",
  "@type": "procedure",
  "@id": "wsmg:health-sciences/medicine/nephrology/neph-010",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:53:50.000Z",
    "modified": "2026-01-13T13:20:00.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "quality-agent"
    ],
    "confidence": 0.96,
    "status": "validated",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/nephrology",
    "subdomain": "renal-replacement-therapy",
    "type": "procedure",
    "difficulty": "advanced",
    "importance": "high",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Kidney Transplant",
    "summary": "Kidney transplantation is the preferred renal replacement therapy for eligible patients with end-stage renal disease (ESRD), offering superior survival and quality of life compared to dialysis. Success depends on careful recipient selection, donor matching, surgical technique, and lifelong immunosuppression to prevent rejection.",
    "key_points": [
      "Living donor transplants have superior graft survival (95% at 5 years) vs deceased donor (85%)",
      "Triple immunosuppression: calcineurin inhibitor + antimetabolite + corticosteroids",
      "Hyperacute rejection: within minutes (preformed antibodies); prevent with crossmatch",
      "Acute cellular rejection: T-cell mediated, treat with pulse steroids or ATG",
      "Antibody-mediated rejection: DSA + C4d deposition; treat with plasmapheresis + IVIG",
      "BK virus nephropathy: major cause of graft loss; reduce immunosuppression"
    ],
    "statement": "Kidney transplantation represents the optimal treatment for ESRD, requiring meticulous donor-recipient matching, perioperative management, and lifelong immunosuppression with vigilant monitoring for rejection and complications.",
    "explanation": {
      "intuition": "Think of kidney transplant as adopting a vital organ that needs protection from the immune system. The recipient's body sees the new kidney as foreign and tries to reject it, so we use immunosuppressive medications as 'peacekeepers' to prevent the immune attack while balancing infection and malignancy risks.",
      "key_insight": "The key to transplant success is the balance between adequate immunosuppression to prevent rejection and minimizing immunosuppression to avoid infections and malignancies. Living donors provide better outcomes due to shorter cold ischemia time and optimal timing.",
      "technical_details": "HLA matching at A, B, DR loci determines compatibility. Panel-reactive antibodies (PRA) measure sensitization. Induction therapy (basiliximab or ATG) provides intense early immunosuppression. Maintenance regimens typically include tacrolimus (target 8-10 ng/mL early, 5-8 later), mycophenolate, and prednisone."
    },
    "definitions_glossary": {
      "allograft": "Organ transplanted between genetically different individuals of same species",
      "HLA_matching": "Compatibility testing of human leukocyte antigens between donor and recipient",
      "crossmatch": "Test detecting preformed recipient antibodies against donor antigens",
      "panel_reactive_antibodies": "Measure of recipient sensitization to HLA antigens (0-100%)",
      "calcineurin_inhibitor": "Immunosuppressant blocking T-cell activation (tacrolimus, cyclosporine)",
      "hyperacute_rejection": "Immediate graft destruction by preformed antibodies within minutes",
      "acute_cellular_rejection": "T-cell mediated rejection typically occurring weeks to months post-transplant",
      "antibody_mediated_rejection": "B-cell/antibody mediated rejection with C4d deposition",
      "donor_specific_antibodies": "Recipient antibodies targeting donor HLA antigens",
      "cold_ischemia_time": "Time organ is preserved outside body; shorter is better",
      "delayed_graft_function": "Need for dialysis within first week post-transplant",
      "BK_virus": "Polyomavirus causing nephropathy in immunosuppressed transplant recipients"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "mechanism": "Surgical implantation of donor kidney with vascular and ureteral anastomoses, requiring immunosuppression to prevent immune-mediated graft destruction",
      "rejection_types": {
        "hyperacute": {
          "timing": "Minutes to hours",
          "mechanism": "Preformed DSA against donor ABO or HLA antigens",
          "findings": ["Immediate graft thrombosis", "DIC", "Graft loss"],
          "prevention": "ABO compatibility and negative crossmatch"
        },
        "acute_cellular": {
          "timing": "Days to months",
          "mechanism": "T-cell mediated attack on graft",
          "findings": ["Creatinine rise", "Interstitial infiltrate on biopsy", "Tubulitis"],
          "treatment": "Pulse methylprednisolone, ATG for steroid-resistant"
        },
        "antibody_mediated": {
          "timing": "Days to years",
          "mechanism": "DSA-mediated complement activation",
          "findings": ["Creatinine rise", "C4d deposition", "Microvascular inflammation"],
          "treatment": "Plasmapheresis, IVIG, rituximab, bortezomib"
        },
        "chronic": {
          "timing": "Months to years",
          "mechanism": "Progressive fibrosis and vascular changes",
          "findings": ["Gradual creatinine rise", "Interstitial fibrosis/tubular atrophy"],
          "treatment": "Optimize immunosuppression, BP and proteinuria control"
        }
      }
    },
    "diagnostic_criteria": {
      "recipient_evaluation": [
        "GFR <20 mL/min or dialysis-dependent",
        "Cardiac clearance (stress test, echo)",
        "Cancer screening up-to-date",
        "Age-appropriate malignancy evaluation",
        "Psychosocial and compliance assessment"
      ],
      "contraindications": {
        "absolute": ["Active infection", "Active malignancy", "Severe cardiac disease", "Active substance abuse", "Non-adherence history"],
        "relative": ["Advanced age (>75)", "Obesity (BMI >40)", "HIV (controlled acceptable)", "Prior malignancy"]
      },
      "rejection_monitoring": [
        "Serum creatinine (most sensitive early marker)",
        "Protocol biopsies (some centers)",
        "Donor-specific antibody monitoring",
        "BK virus PCR surveillance"
      ]
    },
    "treatment_options": {
      "induction_therapy": {
        "low_immunologic_risk": "Basiliximab (IL-2R antagonist) days 0 and 4",
        "high_immunologic_risk": "Antithymocyte globulin (ATG) for sensitized patients"
      },
      "maintenance_immunosuppression": {
        "calcineurin_inhibitor": "Tacrolimus (preferred) or cyclosporine",
        "antimetabolite": "Mycophenolate mofetil or azathioprine",
        "corticosteroid": "Prednisone (may minimize/withdraw in low-risk)"
      },
      "rejection_treatment": {
        "acute_cellular": "Methylprednisolone 500mg IV x 3 days; ATG if steroid-resistant",
        "antibody_mediated": "Plasmapheresis + IVIG Â± rituximab"
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Kidney Transplantation"
    },
    "altLabel": [
      {"@language": "en", "@value": "Renal transplant"},
      {"@language": "en", "@value": "Renal transplantation"},
      {"@language": "en", "@value": "Kidney allograft"}
    ],
    "definition": {
      "@language": "en",
      "@value": "Surgical procedure to implant a donor kidney into a patient with end-stage renal disease, requiring lifelong immunosuppression to prevent rejection"
    },
    "notation": "neph-010",
    "scopeNote": {
      "@language": "en",
      "@value": "Covers recipient evaluation, donor types, immunosuppression, and rejection surveillance"
    }
  },
  "relationships": {
    "skos:broader": [
      {
        "@id": "wsmg:health-sciences/medicine/nephrology/renal-replacement-therapy",
        "skos:prefLabel": "Renal Replacement Therapy"
      }
    ],
    "skos:narrower": [],
    "skos:related": [
      {
        "@id": "wsmg:health-sciences/medicine/nephrology/neph-007",
        "skos:prefLabel": "Dialysis Initiation"
      },
      {
        "@id": "wsmg:health-sciences/medicine/nephrology/neph-005",
        "skos:prefLabel": "Chronic Kidney Disease Staging"
      }
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Kidney_transplantation"
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "70536003",
      "uri": "http://snomed.info/id/70536003",
      "description": "Transplant of kidney"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "Z94.0",
      "uri": "http://hl7.org/fhir/sid/icd-10-cm/Z94.0",
      "description": "Kidney transplant status"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D016030",
      "uri": "http://id.nlm.nih.gov/mesh/D016030",
      "description": "Kidney Transplantation"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Compare outcomes of living vs deceased donor kidney transplants",
      "Describe the immunologic evaluation and crossmatching process",
      "Classify types of rejection by mechanism, timing, and treatment",
      "Design appropriate immunosuppression regimens based on patient risk",
      "Monitor for post-transplant complications including BK nephropathy"
    ],
    "clinical_pearls": [
      "Living donor transplant: 95% 5-year graft survival vs 85% deceased donor",
      "Negative crossmatch is MANDATORY to prevent hyperacute rejection",
      "Tacrolimus trough targets: 8-10 ng/mL early, 5-8 ng/mL after 6 months",
      "Rising creatinine = biopsy to distinguish rejection from other causes",
      "BK viremia >10,000 copies/mL: reduce immunosuppression"
    ],
    "board_yield": "HIGH",
    "estimated_time": "30min",
    "target_audience": [
      "nephrology_fellows",
      "transplant_surgeons",
      "internal_medicine_residents"
    ],
    "common_misconceptions": [
      "ABO incompatibility is absolute contraindication - desensitization protocols exist",
      "Rejection always causes symptoms - can be subclinical",
      "Immunosuppression doses remain constant - require ongoing adjustment"
    ]
  },
  "prerequisites": [
    {
      "@id": "wsmg:health-sciences/medicine/nephrology/neph-005",
      "skos:prefLabel": "Chronic Kidney Disease Staging"
    },
    {
      "@id": "wsmg:health-sciences/medicine/nephrology/neph-007",
      "skos:prefLabel": "Dialysis Initiation"
    }
  ],
  "related_concepts": [
    "immunosuppression",
    "HLA matching",
    "graft rejection",
    "calcineurin inhibitors",
    "organ allocation"
  ],
  "evidence": {
    "citations": [
      {
        "authors": "Loupy A, Haas M, Roufosse C, et al.",
        "title": "The Banff 2019 Kidney Meeting Report",
        "journal": "Am J Transplant",
        "year": 2020,
        "volume": "20",
        "pages": "804-814",
        "doi": "10.1111/ajt.15875"
      }
    ],
    "confidence_rationale": "Based on established transplant guidelines and Banff classification"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-13T13:20:00.000Z",
    "sources": [
      {
        "source": "Brenner and Rector's The Kidney, 11th ed. Elsevier, 2020.",
        "type": "textbook",
        "year": 2020,
        "isbn": "978-0323532655",
        "relevance": "Comprehensive nephrology reference"
      },
      {
        "source": "KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. 2009.",
        "type": "guideline",
        "year": 2009,
        "relevance": "Evidence-based transplant management"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.94,
    "completeness": 0.95,
    "accuracy": 0.96,
    "clarity": 0.93,
    "clinical_relevance": 0.97,
    "last_assessed": "2026-01-13T13:20:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Kidney_transplantation",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q738161"
}